MedPath

Romiplostim in Inherited marrow failure syndromes - Safety and Efficacy

Phase 2
Conditions
Health Condition 1: D610- Constitutional aplastic anemia
Registration Number
CTRI/2024/03/063966
Lead Sponsor
INDIAN COUNCIL OF MEDICAL RESEARCH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients with IBMFS including Fanconi anemia, dyskeratosis congenita causing cytopenias Hb less than 8 gram per decilitre, ANC less than 500 cells or Platelet count less than 30,000 per microlitre or bone marrow cellularity less than 25 percent and with danazol resistance or intolerance

Exclusion Criteria

Known hypersensitivity or past use of Romiplostim, history of thrombosis, patients with IBMF with co-existing myelodysplasia or malignancies and organ dysfunction; presence of FANCD mutation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
A. Twenty five percent reduction in transfusion requirement compared to baseline <br/ ><br>B. Achieving platelet count more than 30,000 per microlitre, Hb more than 8gram per decilitre or ANC more than 500 per microlitre compared to baseline <br/ ><br> C. Transfusion independence for 4 consecutive weeks <br/ ><br> D. Bone marrow response, defined as an increase in bone marrow cellularity by at least two-fold from baseline. <br/ ><br>Timepoint: 12 and 24 weeks
Secondary Outcome Measures
NameTimeMethod
The following known drug related adverse reactions will be monitored <br/ ><br>1. Occurrence of clonal evolution <br/ ><br> 2. Thrombotic events <br/ ><br>3. Allergy/ hypersensitivity <br/ ><br>4. Pain at injection site <br/ ><br>5. Headache <br/ ><br> 6. Myalgia <br/ ><br>7. Fatigue <br/ ><br>8. Dizziness <br/ ><br>9. Transaminitis <br/ ><br>10. Any other symptom reported by the patient up to 4 weeks after study completion. <br/ ><br> <br/ ><br> Along with disease related adverse events like <br/ ><br> 1. Infection <br/ ><br> 2. Anemia <br/ ><br>3. Bleeding <br/ ><br>Timepoint: weekly basis from week 1 to week 36
© Copyright 2025. All Rights Reserved by MedPath